The safety of cefepime in the treatment of infection

Expert Opinion on Drug Safety

Volumn 7, Issue 4, 2008, Pages 377-387

  Drago, Lorenzo ^a   De Vecchi, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cefepime; Drug safety; Fourth generation cephalosporins; Severe infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ABNORMAL RESPIRATORY SOUND; AGITATION; ALLERGIC REACTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANXIETY; APHASIA; ATAXIA; ATTENTION DISTURBANCE; BACTERIAL INFECTION; BONE INFECTION; BRAIN DISEASE; CHOREOATHETOSIS; CLINICAL TRIAL; CLONUS; COMA; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; CONVULSION; CREATININE BLOOD LEVEL; DELIRIUM; DIARRHEA; DISORIENTATION; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FEBRILE NEUTROPENIA; FECES MICROFLORA; FEVER; FLAPPING TREMOR; GENE MUTATION; GYNECOLOGIC INFECTION; HALLUCINATION; HEMOLYSIS; HOSPITAL INFECTION; HUMAN; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; IN VITRO STUDY; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; IRRITABILITY; KIDNEY DYSFUNCTION; LANGUAGE DISABILITY; LEUKOCYTE COUNT; MALAISE; MONOTHERAPY; MORTALITY; MUSCLE TWITCH; MYOCLONUS; NAUSEA; NEUROTOXICITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERITONITIS; PHLEBITIS; PROTHROMBIN TIME; REFLEX DISORDER; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STUPOR; THRUSH; TREMOR; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; VAGINITIS; VOMITING;

BACTERIAL INFECTIONS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROTOXICITY SYNDROMES;

EID: 48749087664     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.4.377     Document Type: Review

References (100)

1. Wynd MA, Paladino JA. Cefepime: a fourth generation parenteral cephalosporin. Ann Pharmacother 1996;30:1414-24
2. Woods M. Cefepime: a new generation cephalosporin. J Infect Dis Pharmacother 1997;2:5-28
3. Hancock REW, Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother 1992;29(Suppl A):1-6
4. Nikaido H, Liu W, Rosenberg EY. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother 1990;34:337-42
5. Gillum JG, Polk RE. Focus on cefepime: a fourth generation, extended-spectrum cephalosporin. Hosp Formul 1994;29:503-14
6. Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob Agents Chemother 1993;37:2045-53
7. Pucci MJ, Boice-Sowek J, Kessler RE, Dougherty TJ. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother 1991;35:2312-7
8. Sanders CC. Cefepime: the next generation? Clin Infect Dis 1993;17:369-79
9. Jones RN, Fuchs PC. Activity of cefepime (BMY-28142) and cefpirome (HR-810) against gram-negative bacilli resistant to cefotaxime or ceftazidime. J Antimicrob Chemother 1989;23:163-5
10. Sader HS, Fritsche TR, Jones RN. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998 - 2003). Diagn Microbiol Infect Dis 2005;52:265-73
11. Gomez-Lus R, Navarro C, Egido P, et al. In vitro activity of cefepime and cefotaxime compared to six other agents against 350 penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Chemother 2000;12:17-21
12. Bell JM, Turnidge JD; Cefepime Study Group. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents. Pathology 2001;33:53-60
13. Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001 - 2002). Diagn Microbiol Infect Dis 2003;47:435-40
14. Huang SS, Lee SC, Lee N, et al. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. J Microbiol Immunol Infect 2007;40:134-40
15. Jones RN, Mutnick AH, Varnam DJ. Impact of modified nonmeningeal Streptococcus pneumoniae interpretative criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol 2002;40:4332-3
16. Fontana R, Lo Cascio G, Ligozzi M, et al. Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999. Eur J Clin Microbiol Infect Dis 2001;20:854-63
17. Jones RN, Pfaller MA, Doern GV, et al. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis 1998;30:45-52
18. Sorlózano A, Gutiérrez J, Romero JM, et al. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 2007;47:413-6
19. Casellas JM, Tome G, Bantar C, et al. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillintazobactam against selected bacterial isolates recovered from hospitalized patients. Diagn Microbiol Infect Dis 2003;47:527-37
20. Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215-27
21. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 2008;61:595-602
22. Korten V, Ulusoy S, Zarakolu P, Mete B; Turkish MYSTIC Study Group. Antibiotic resistance surveillance over a 4-year period (2000 - 2003) in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis 2007;59:453-7
23. Strateva T, Ouzounova-Raykova V, Markova B, et al. Problematic clinical isolates of Pseudamonas aeruginosa from the university hospitals in Sofia, Bulgaria: current status of antimicrobial resistance and prevailing resistance mechanisms. J Med Microbiol 2007;56:956-63
24. Cavallo JD, Hocquet D, Plesiat P, et al. GERPA (Groupe d'Etude de la Résistance de Pseudomonas aeruginosa aux antibiotiques). Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. J Antimicrob Chemother 2007;59:1021-4
25. Jones RN, Sader HS, Fritsche TR, Pottumarthy S. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007;57:109-16
26. Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in Gram negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002;14:140-6
27. Hamilton-Miller JMT, Shah S. Comparative anti-anaerobic activity of Men 10700, a penem antibiotic. J Antimicrob Agents 1998;10:321-4
28. Fung-Tomc JC, Gradelski E, Huczko E, et al. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:1289-93
29. Carsenti-Etesse H, Cavallo JD, Roger PM, et al. Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2001;7:144-51
30. Sanders CC, Sanders WE. Type 1 beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis 1986;154:792-800
31. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994;47:471-505
32. Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother 1993;32(Suppl B):87-94
33. Sanders CC. In vitro activity of fourth generation cephalosporins against Enterobacteriaceae producing extended spectrum β-lactamases. J Chemother 1996;8(Suppl 2):57-62
34. Livermore D. Defining an extended spectrum β-lactamase. Clin Microbiol Infect 2008;14(Suppl 1):3-10
35. Giamarellou H. β-lactams without a suicide inhibitor. Clin Microbiol Infect 2008;14(Suppl 1):194-7
36. Koh TH, Wang G, Koh TY. High-level cefepime resistance in Escherichia coli from Singapore producing OXA-1 beta-lactamase. Int J Antimicrob Agents 2008;31:382-3
37. Nakae T, Nakajima A, Ono T, et al. Resistance to β-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and β-lactamase. Antimicrob Agents Chemother 1999;43:1301-3
38. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(Suppl 2):S49-56
39. Masuda N, Sakagawa E, Ohya S, et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:3322-7
40. Hocquet D, Nordmann P, El Garch F, et al. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1347-51
41. Choi SH, Lee JE, Park SJ, et al. Emergence of antibiotic resistance during therapy for infections caused by AmpC β-lactamase ptoducing Enterobactericeae: implications for antibiotic use. Antimicrob Agents Chemother 2008;52:995-1000
42. Bacher K, Schaeffer M, Lode H, et al. Multiple dose pharmacokinetics, safety and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother 1992;30:365-75
43. Samonis G, Thomakos N, Liakakos T, et al. Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. Chemotherapy 2001;47:350-3
44. Paterson DL, Muto CA, Ndirangu M, et al. Acquisition of vancomycin-resistant Enterococcus rectal colonization among intensive care unit patients treated with piperacillin/tazobactam versus cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 2008;52:465-9
45. Ryback M. The pharmacokinetic profile of a new generation of parenteral cephalosporin. Am J Med 1996;100(Suppl 6A):39-44
46. Garrelts JC, Wagner DJ. The pharmacokinetics, safety, and tolerance of cefepime administered as an intravenous bolus or as a rapid infusion. Ann Pharmacother 1999;33:1258-61
47. Bernard E, Breills D, Bru JP, et al. Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach. Clin Microbiol Infect 2003;9:339-48
48. Barbhaiya RH, Knupp CA, Tenney J, et al. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol 1990;30:900-10
49. Kovarick JM, Ter Maaten JC, Rademaker CM, et al. Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother 1990;34:1885-8
50. Kieft H, Hoepelman AI, Knupp CA, et al. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993;32(Suppl B):117-22
51. Lipman J, Wallis S, Boots R. Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003;97:1149-54
52. Tam VH, McKinnon PS, Akins RL, et al. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003;47:1853-61
53. Cronqvist J, Nilsson-Ehle I, Oqvist B, Norrby SR. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment. Antimicrob Agents Chemother 1992;36:2676-80
54. Chapman TM, Perry CM. Cefepime. A review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003;2:75-107
55. Roberts JA, Webb SAR, Lipman J. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. Int J Antimicrob Agents 2007;29:117-28
56. Grossman RF, Campbell DA, Landis SJ, et al. Treatment of community-acquired pneumonia in the elderly: the role of cefepime, a fourth generation cephalosporin. J Antimicrob Chemother 1999;43:549-54
57. Paladino JA, Eubanks DA, Adelman MH, Schentag JJ. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia. J Am Geriatr Soc 2007;55:651-7
58. Konstantinou K, Baddam K, Lanka A, et al. Cefepime versus ceftazidime for treatment of pneumonia. J Int Med Res 2004;32:84-93
59. Ambrose PG, Richerson MA, Stanton ME, et al. Cost-effectiveness analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia. Infect Dis Clin Pract 1999;8:245-51
60. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442-7
61. Beaucaire G, Nicolas MH, Martin C, et al. Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study. Ann Fr Anesth Reanim 1999;18:186-95
62. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51
63. Ramphal R, Gucalp R, Rotstein C, et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996;100(Suppl 6A):S83-9
64. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176-89
65. Falagas ME, Vardakas KZ, Samonis G. Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin 2008;24:215-35
66. Glasmacher A, von Lilienfeld-Toal M, Schulte S, et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect 2005;11(Suppl 5):17-23
67. Fleming DR, Ziegler C, Baize T, et al. Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients. Am J Clin Oncol 2003;26:285-8
68. Tamura K, Imajo K, Akijama N, et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004;39(Suppl 1):S15-24
69. Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;98:1039-47
70. Borbolla JR, Lopez-Hernandez MA, Gonzalez-Avante M, et al. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukaemia patients. Chemotherapy 2001;47:381-4
71. Ariffin H, Ai CL, Lee CL, Abdullah WA. Cefepime monotherapy for treatment of febrile neutropenia in children. J Paediatr Child Health 2006;42:781-4
72. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol 2006;23:177-86
73. Chuang YY, Hung IJ, Yang CP, et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer. Pediatr Infect Dis J 2002;21:203-9
74. Hamidah A, Lim YS, Zulkifli SZ, et al. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2007;48:615-9
75. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther 2007;29:889-99
76. Wong KM, Chan YH, Cheung CY, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001;38:127-31
77. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. Arch Surg 1997;132:1294-302
78. Huang CK, Chen YS, Lee SS, et al. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. J Microbiol Immunol Infect 2002;35:159-67
79. Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Am J Med 1996;100:S76-82
80. Holloway WJ, Palmer D. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. Am J Med 1996;100:S52-9
81. Badarò R, Molinar F, Seas C, et al. A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections. Braz J Infect Dis 2002;6:206-18
82. Rennie RP, Jones RN, Mutnick AH; SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45:287-93
83. Schwartz R, Das-Young LR, Ramirez-Ronda C, Frank E. Current and future management of serious skin and skin-structure infections. Am J Med 1996;100(Suppl 6A):S90-5
84. Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. Clin Microbiol Infect 2006;12:1030-3
85. Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 1996;100(Suppl 6A):S68-75
86. Bradley JS, Arrieta A. Empiric use of cefepime in the treatment of lower respiratory tract infections in children. Pediatr Infect Dis J 2001;20:343-9
87. Mustafa MM, Carlson L, Tkaczewski I, et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 2001;20:362-9
88. Sáez-Llorens X, O'Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001;20:356-61
89. Arrieta AC, Bradley JS. Empiric use of cefepime in the treatment of serious urinary tract infections in children. Pediatr Infect Dis J 2001;20:350-5
90. Chow KM, Szeto CC, Che-Fai Hui A, et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003;23:369-73
91. Abanades S, Nolla J, Rodríguez-Campello A, et al. Reversible coma secondary to cefepime neurotoxicity. Ann Pharmacother 2004;38:606-8
92. Dakdouki GK, Al-Awar GN. Cefepime-induced encephalopathy. Int J Infect Dis 2004;8:59-61
93. Lam S, Gomolin IH. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 2006;26:1169-74
94. Bragatti JA, Rossato R, Ziomkowski S, Kliemann FA. Cefepime-induced encephalopathy: clinical and electroencephalographic features in seven patients. Arq Neuropsiquiatr 2005;63:87-92
95. Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 2008;23:966-70
96. Sugimoto U, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003;45:304-14
97. Early communication about an ongoing safety review: cefepime (marketed as Maxipime). Available from: www.fda.gov/Cder/Drug/early_comm/ cefepime.htm [Last accessed 20 December 2007]
98. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime; a systematic review and meta-analysis. Lancet Infect Dis 2007;7:338-48
99. Hoepelman AI, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother 1993;32(Suppl B):175-86
100. Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol 2007;7:459-69